Study reports D-allulose mitigates cognitive impairment and brain mitochondrial dysfunction in accelerated-aging rats

Researchers reported that oral administration of the low-calorie rare sugar D-allulose significantly attenuated cognitive decline and brain mitochondrial oxidative stress in a rat model of accelerated aging.

A preclinical study published in The Journal of Nutrition evaluated the neuroprotective effects of D-allulose, a low-calorie rare sugar, in Wistar rats undergoing D-galactose-induced accelerated aging.

The administration of D-allulose (1.9 g/kg/day by oral gavage for 12 weeks) significantly increased spatial learning and memory performance, with treated rats achieving 7.4 ± 0.50 target quadrant entries in the Morris Water Maze compared to 5.6 ± 0.89 in the untreated D-galactose group (P = 0.042).

Electrophysiological recordings showed that D-allulose restored synaptic plasticity, increasing the mean normalized hippocampal fEPSP slope to 155.5% ± 8.95% compared to 99.0% ± 1.86% in the untreated aging model group (P = 0.018).

Comparative groups treated with the prebiotic inulin (2.0 g/kg/day) did not exhibit statistically significant improvements in spatial learning or electrophysiological metrics.

Furthermore, D-allulose-treated rats exhibited significantly reduced mitochondrial reactive oxygen species (ROS) production (P = 0.023) and decreased brain malondialdehyde (MDA) levels (P = 0.013), indicating a mitigation of aging-associated brain oxidative stress.

While D-allulose has previously shown metabolic benefits in obese-insulin-resistant animal models, this is the first study to directly evaluate and demonstrate its efficacy in countering age-associated brain pathologies.

The failure of inulin to produce equivalent improvements indicates that the neuroprotective mechanism of D-allulose is distinct from general dietary fiber or basic prebiotic actions, suggesting specific metabolic or mitochondrial signaling pathways are involved.

These findings provide a mechanistic basis for exploring low-calorie rare sugars as scalable, low-toxicity preventive interventions for age-related cognitive decline.

The positive preclinical data may encourage developers in the metabolic-health and longevity sectors to expand research into rare sugars and related caloric-restriction mimetics.

Though preclinical, the clear behavioral and physiological endpoints provide a baseline for competitive comparisons against other early-stage mitochondrial and metabolic interventions in the longevity space.

Further preclinical studies evaluating the long-term safety and efficacy of D-allulose in naturally aged animal models, rather than chemically accelerated aging models.

Potential translational human clinical trials examining whether dietary supplementation with D-allulose can safely modulate cognitive and mitochondrial biomarkers in older adults.